0.990
0.04 (4.21%)
| Penutupan Terdahulu | 0.950 |
| Buka | 0.937 |
| Jumlah Dagangan | 11,376 |
| Purata Dagangan (3B) | 204,055 |
| Modal Pasaran | 75,085,072 |
| Harga / Jualan (P/S) | 9.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 - 12 May 2025 |
| Margin Operasi (TTM) | -571.68% |
| EPS Cair (TTM) | -0.450 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.80% |
| Nisbah Semasa (MRQ) | 4.49 |
| Aliran Tunai Operasi (OCF TTM) | -18.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Clearside Biomedical, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 7.76% |
| % Dimiliki oleh Institusi | 20.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Carmignac Gestion | 31 Dec 2024 | 1,933,531 |
| Brown Wealth Management, Llc | 31 Dec 2024 | 100,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 6.00 (HC Wainwright & Co., 506.06%) | Beli |
| 6.00 (Chardan Capital, 506.06%) | Beli | |
| Median | 5.50 (455.56%) | |
| Rendah | 4.00 (Needham, 304.04%) | Beli |
| Purata | 5.25 (430.30%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 0.960 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Mar 2025 | 6.00 (506.06%) | Beli | 0.990 |
| 06 Mar 2025 | 6.00 (506.06%) | Beli | 0.976 | |
| Chardan Capital | 28 Mar 2025 | 6.00 (506.06%) | Beli | 0.950 |
| Citizens Capital Markets | 28 Mar 2025 | 5.00 (405.05%) | Beli | 0.950 |
| Needham | 28 Mar 2025 | 4.00 (304.04%) | Beli | 0.950 |
| 06 Mar 2025 | 6.00 (506.06%) | Beli | 0.976 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |